Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGH | Q92820 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | CPA3 | P15088 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7604513 | 0.87 | GGH (0.42) | GGHFOLH1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL5052928 | 0.85 | GGH (0.40) | GGHFOLH1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL8065615 | 0.84 | FOLH1 (0.41) | GGHFOLH1NAALAD2 | |
| SCHEMBL5051128 | 0.83 | GGH (0.39) | GGHFOLH1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL7607505 | 0.79 | GGH (0.51) | GGHFOLH1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL5057917 | 0.77 | FOLH1 (0.48) | GGHFOLH1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL8457126 | 0.77 | GGH (0.44) | GGHFOLH1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL7605307 | 0.75 | GABRP (0.47) | GGHFOLH1CYP1A2NAALAD2 | |
| SCHEMBL5052848 | 0.75 | CYP2D6 (0.48) | FOLH1ALDH1A1CYP2D6TSHRCPA3 | |
| SCHEMBL5217064 | 0.75 | CYP2D6 (0.57) | GGHALDH1A1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999033848-B1 | PROCESS FOR PREPARING ENANTIOMER-ENRICHED HYDROXYPHOSPHINYL DERIVATIVES | GUILFORD PHARM INC (US) | 1999-08-12 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| EP-0994707-A4 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARM INC (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-0994707-A1 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| US-6025345-A | NOVEL PHOSPHONATE DERIVATIVES, HYDROXYPHOSPHINYL DERIVATIVES, AND PHOSPHORAMIDATE DERIVATIVES THAT INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY, | GUILFORD PHARMACEUTICALS INC. (US) | 2000-02-15 | — | — | US | disclosed |
| WO-1998053812-A1 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | GGH 1030/4885FOLH1 1/4885ALDH1A1 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.